Literature DB >> 26725175

Hippo pathway and breast cancer stem cells.

Marcello Maugeri-Saccà1, Ruggero De Maria2.   

Abstract

Tumors contain a specialized subset of cells with unique properties, such as self-renewal and tumorigenic potential. These cancer stem-like cells (CSCs) are supposed to be responsible for therapeutic resistance and metastatic spread. Functional characterization of breast CSCs (BCSCs) is beginning to shed light on molecular networks which are specifically activated in this cellular compartment, and that account for the retention/acquisition of stem-like features. The Hippo tumor suppressor pathway has increasingly been tied to breast cancer. Altered Hippo activity, or Hippo-independent mechanisms, mediate the activation of the Hippo transducers TAZ and YAP. When this occurs, cancer cells acquire more aggressive traits. In the realm of BCSCs, improper TAZ/YAP activity sustains self-renewal, resistance to conventional anticancer agents, and metastatic dissemination. In this review, we highlight the involvement of TAZ and YAP in mammary gland development and in BCSCs. We also discuss potential strategies for transferring this information into the clinical setting.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cancer stem Cells; Hippo pathway

Mesh:

Substances:

Year:  2015        PMID: 26725175     DOI: 10.1016/j.critrevonc.2015.12.004

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  17 in total

1.  Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation.

Authors:  Ya-Wen Ma; Yi-Zhi Liu; Jing-Xuan Pan
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.

Authors:  Samantha Guillemette; Charlène Rico; Philippe Godin; Derek Boerboom; Marilène Paquet
Journal:  J Mammary Gland Biol Neoplasia       Date:  2017-08-18       Impact factor: 2.673

3.  Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells.

Authors:  Zhifen Zhou; Min Li; Lin Zhang; Hong Zhao; Özgür Şahin; Jing Chen; Jean J Zhao; Zhou Songyang; Dihua Yu
Journal:  Cancer Res       Date:  2018-02-12       Impact factor: 12.701

4.  Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.

Authors:  Cristiana Ercolani; Anna Di Benedetto; Irene Terrenato; Laura Pizzuti; Luigi Di Lauro; Domenico Sergi; Francesca Sperati; Simonetta Buglioni; Maria Teresa Ramieri; Lucia Mentuccia; Teresa Gamucci; Letizia Perracchio; Edoardo Pescarmona; Marcella Mottolese; Maddalena Barba; Patrizia Vici; Ruggero De Maria; Marcello Maugeri-Saccà
Journal:  Cancer Biol Ther       Date:  2017-04-07       Impact factor: 4.742

Review 5.  Proteomics and its applications in breast cancer.

Authors:  Anca-Narcisa Neagu; Danielle Whitham; Emma Buonanno; Avalon Jenkins; Teodora Alexa-Stratulat; Bogdan Ionel Tamba; Costel C Darie
Journal:  Am J Cancer Res       Date:  2021-09-15       Impact factor: 5.942

6.  MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.

Authors:  Maroof Alam; Audrey Bouillez; Ashujit Tagde; Rehan Ahmad; Hasan Rajabi; Takahiro Maeda; Masayuki Hiraki; Yozo Suzuki; Donald Kufe
Journal:  Mol Cancer Res       Date:  2016-09-22       Impact factor: 5.852

Review 7.  The HIPPO pathway in gynecological malignancies.

Authors:  Dongying Wang; Jiaxing He; Junxue Dong; Thomas F Meyer; Tianmin Xu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

Review 8.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

Review 9.  The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review.

Authors:  Anastasios Kyriazoglou; Michalis Liontos; Roubini Zakopoulou; Maria Kaparelou; Anna Tsiara; Alkistis Maria Papatheodoridi; Rebecca Georgakopoulou; Flora Zagouri
Journal:  Breast Care (Basel)       Date:  2020-05-12       Impact factor: 2.860

10.  MST1 inhibits the progression of breast cancer by regulating the Hippo signaling pathway and may serve as a prognostic biomarker.

Authors:  Xiang Jin; Lihua Zhu; Sheng Xiao; Zhuhong Cui; Jing Tang; Jiangyong Yu; Mingjun Xie
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.